Show simple item record

dc.contributor.authorL. Kramp, Karien_US
dc.contributor.authorDeWitt, Kristinen_US
dc.contributor.authorW. Flora, Jasonen_US
dc.contributor.authorC. Muddiman, Daviden_US
dc.contributor.authorM. Slunt, Kellien_US
dc.contributor.authorHouston, Todden_US
dc.date.accessioned2017-05-03T13:55:49Z
dc.date.available2017-05-03T13:55:49Z
dc.date.issued2005en_US
dc.identifier.issn00404039en_US
dc.identifier.doi10.1016/j.tetlet.2004.11.112en_US
dc.identifier.urihttp://hdl.handle.net/10072/4947
dc.description.abstractThe Leishmania lipophosphoglycan (LPG) is the most abundant cell surface glycoconjugate of a family of infectious protozoa. Pentamidine, a common drug used in the treatment of Leishmania infections, has been modified with boronic acids so that it might bind more selectively to the phosphodisaccharide repeating unit of the LPG. This could serve to target the drug to the protozoan surface and increase its efficacy in vivoen_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherElsevier Ltd / Pergmonen_US
dc.publisher.placeOxford, UKen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom695en_US
dc.relation.ispartofpageto698en_US
dc.relation.ispartofjournalTetrahedron Lettersen_US
dc.relation.ispartofvolume46en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchcode250302en_US
dc.titleDerivatives of pentamidine designed to target the Leishmania lipophosphoglycanen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2015-05-11T00:49:20Z
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record